Figure 1.

Variants detected in the human challenge trial. A, Diagram detailing selection of participants for sequencing analysis. B, Theoretical viral load patterns for each group. These data are not from any participants but an example of viral load patterns that could be observed in each group. C and D, Viral shedding patterns for (C) LLOQ and (D) N:L139I for each participant from the human challenge trial with treatment-emergent mutations. Shaded triangles indicate EDP-938 dosing. Participant 20027 was assigned to a once daily treatment group. As such, this participant received a placebo for 1 of the 2 daily doses (open triangles). Light dashed line indicates the LLOQ (2.8 log₁₀ copies/mL). Bold dashed line indicates the LLOD (1.4 log₁₀ copies/mL). No mapped reads indicate no sequencing reads were able to be aligned to the RSV M37b reference genome. Abbreviations: LD, loading dose; LLOD, lower limit of detection; LLOQ, lower limit of quantification; N, nucleoprotein; RSV, respiratory syncytial virus; WT, wild type.